December 15, 2016 05:19 PM EST
Pharma

Af­ter some care­ful think­ing, Cel­gene strikes a $295M dis­cov­ery deal on neu­rode­gen­er­a­tion

John Carroll

Editor & Founder

A year ago, Cel­gene’s Bob Hug­in told a room­ful of re­porters at JP Mor­gan — which in­clud­ed me — that af­ter some care­ful con­tem­pla­tion he …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

A service from the Financial Times